The 68th
Scientific Meeting
초록접수 미리보기
| 19S-043 |
New apply of Buprenorphine patch on Pain Site in Patients of Knee Osteoarthritis
아주대학교 의과대학 마취통증의학교실
Introduction
OA is already one of the ten most disabling diseases in developed countries. Patients are sometimes prescribed opioids. We suggest the method of the combination the merit of systemic opioids and peripheral opioids in knee OA patients. We had applied buprenorphine patch at pain site of knee joints in knee OA patients, and they had showed good analgesic effect and low side effects
Method
We retrospectively enrolled 112 patients with knee OA who were not responds to conventional therapy. As a primary outcome, NRS was checked before and at 2 weeks, and 1months when buprenorphine applied. As secondary outcome, side effects of buprenorphine patchs were checked and recorded. Thertiary outcome was compliance of buprenorphine patch. In conventional applied buprenorphine patch group and pain site applied buprenorphine group, NRS, side effects and compliance were checked and compared between both groups
Result
In Pain site applied buprenorphine group, NRS after buprenorphine apply were more decreased than NRS in Conventional applied buprenorphine group. In Conventional applied buprenorphine group, total side effects were 80 cases in 125 patients (GI:33, CNS:24, Skin problem: 15, Others:8). In Pain site applied buprenorphine group, total side effects were 17 cases in 88 patients (GI:2, GU:1, Skin problem:14). In Conventional applied buprenorphine group, maintenance numbers of buprenorphine patch were 47 cases in 125 patients (37.6%), but in pain site applied buprenorphine group, maintenance numbers of buprenorphine patch were 73 cases in 88 patients (83.0%).
Conclusion
New apply of buprenorphine patch on pain site in knee OA patients will be more effective, less adversely effective and more compliant than conventional apply of buprenorphine
Ref.
1. Yoon et al. BMC Musculoskeletal Disorders (2017) 18:337
2. Dahan A, Yassen A, Romberg R, Sarton E, Teppema L, Olofsen E, et. al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006;96:627han A, Filitz J, Langford R, Likar R, et al. Current , knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010;10:428.
OA is already one of the ten most disabling diseases in developed countries. Patients are sometimes prescribed opioids. We suggest the method of the combination the merit of systemic opioids and peripheral opioids in knee OA patients. We had applied buprenorphine patch at pain site of knee joints in knee OA patients, and they had showed good analgesic effect and low side effects
Method
We retrospectively enrolled 112 patients with knee OA who were not responds to conventional therapy. As a primary outcome, NRS was checked before and at 2 weeks, and 1months when buprenorphine applied. As secondary outcome, side effects of buprenorphine patchs were checked and recorded. Thertiary outcome was compliance of buprenorphine patch. In conventional applied buprenorphine patch group and pain site applied buprenorphine group, NRS, side effects and compliance were checked and compared between both groups
Result
In Pain site applied buprenorphine group, NRS after buprenorphine apply were more decreased than NRS in Conventional applied buprenorphine group. In Conventional applied buprenorphine group, total side effects were 80 cases in 125 patients (GI:33, CNS:24, Skin problem: 15, Others:8). In Pain site applied buprenorphine group, total side effects were 17 cases in 88 patients (GI:2, GU:1, Skin problem:14). In Conventional applied buprenorphine group, maintenance numbers of buprenorphine patch were 47 cases in 125 patients (37.6%), but in pain site applied buprenorphine group, maintenance numbers of buprenorphine patch were 73 cases in 88 patients (83.0%).
Conclusion
New apply of buprenorphine patch on pain site in knee OA patients will be more effective, less adversely effective and more compliant than conventional apply of buprenorphine
Ref.
1. Yoon et al. BMC Musculoskeletal Disorders (2017) 18:337
2. Dahan A, Yassen A, Romberg R, Sarton E, Teppema L, Olofsen E, et. al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006;96:627han A, Filitz J, Langford R, Likar R, et al. Current , knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010;10:428.
|
|
